Small-cell carcinoma of the esophagus and gastroesophageal junction: Review of the Memorial Sloan-Kettering experience Journal Article
| Authors: | Ku, G. Y.; Minsky, B. D.; Rusch, V. W.; Bains, M.; Kelsen, D. P.; Ilson, D. H. |
| Article Title: | Small-cell carcinoma of the esophagus and gastroesophageal junction: Review of the Memorial Sloan-Kettering experience |
| Abstract: | Background: Esophageal small-cell carcinoma (SCC) is rare, highly malignant and the optimal treatment approach has not been defined. Patients and methods: We report the largest single-institution retrospective review of patients with esophageal and gastroesophageal (GE) junction SCC. Results: Twenty-five patients were identified, with complete records available for 22. Eighty-two percent were male, 82% had pure SCC histology and 86% of tumors were in the lower esophagus or GE junction. On the basis of the Veterans' Administration Lung Study Group criteria, 14 patients (64%) presented with limited disease (LD). Median survival was 19.8 months (range, 1.5 months to 11.2+ years); for LD patients, 22.3 months (range, 6 months to 11.2+ years); for extensive disease (ED) patients, 8.5 months (range, 1.5 months to 2.2 years, P = 0.02). With a median follow-up of 38 months, six patients (27%) are alive, one with ED and five with LD. Two LD patients are alive and free of disease for >5 years. Four of the five LD patients who are long-term survivors received induction chemotherapy followed by chemoradiotherapy without surgery. Conclusions: Our data indicate that patients with LD esophageal SCC treated with induction chemotherapy followed by consolidative chemoradiation can achieve long-term survival. The contribution of surgery remains unclear. © The Author 2007. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. |
| Keywords: | adult; cancer chemotherapy; cancer survival; clinical article; human tissue; treatment outcome; aged; middle aged; survival rate; retrospective studies; histopathology; review; cisplatin; doxorubicin; fluorouracil; cancer growth; drug withdrawal; side effect; paclitaxel; adjuvant therapy; cancer adjuvant therapy; cancer radiotherapy; disease free survival; combined modality therapy; chemotherapy; recurrent cancer; lymphatic metastasis; neoplasm staging; cancer palliative therapy; carboplatin; multiple cycle treatment; neoplasm recurrence, local; etoposide; radiotherapy; vincristine; irinotecan; survival time; folinic acid; drug response; surgery; esophagus resection; second cancer; platinum complex; drug substitution; stomach carcinoma; esophagus carcinoma; esophagus; esophageal neoplasms; chemoradiotherapy; small cell carcinoma; esophagogastric junction; carcinoma, small cell; drug intermittent therapy; gastroesophageal junction; gastroesophageal junction small cell carcinoma |
| Journal Title: | Annals of Oncology |
| Volume: | 19 |
| Issue: | 3 |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2008-01-01 |
| Start Page: | 533 |
| End Page: | 537 |
| Language: | English |
| DOI: | 10.1093/annonc/mdm476 |
| PUBMED: | 17947223 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 21" - "Export Date: 17 November 2011" - "CODEN: ANONE" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work